Peripheral T-cell lymphomas(PTCLs)encompass a biologically diverse group of non-Hodgkin lymphomas derived from mature T-lymphocytes.Most PTCLs present as nodal diseases and include several subtypes characterized by di...Peripheral T-cell lymphomas(PTCLs)encompass a biologically diverse group of non-Hodgkin lymphomas derived from mature T-lymphocytes.Most PTCLs present as nodal diseases and include several subtypes characterized by distinct clinical and pathologic features,and will be the focus of this editorial.The PTCL group presenting as rare distinctive extranodal diseases will not be discussed.While T-cell neoplasms,like B-cell lymphomas,recapitulate stages of normal differentiation,the biology is notably intricate and exhibits remarkable plasticity.展开更多
Lymphoma is a diverse disease with a variety of different subtypes,each characterized by unique pathophysiology,tumor microenvironment,and underlying signaling pathways leading to oncogenesis.With our increasing under...Lymphoma is a diverse disease with a variety of different subtypes,each characterized by unique pathophysiology,tumor microenvironment,and underlying signaling pathways leading to oncogenesis.With our increasing understanding of the molecular biology of lymphoma,there have been a number of novel targeted therapies and immunotherapy approaches that have been developed for the treatment of this complex disease.Despite rapid progress in the field,however,many patients still relapse largely due to the development of drug resistance to these therapies.A better understanding of the mechanisms underlying resistance is needed to develop more novel treatment strategies that circumvent these mechanisms and design better treatment algorithms that personalize therapies to patients and sequence these therapies in the most optimal manner.This review focuses on the recent advances in therapies in lymphoma,including targeted therapies,monoclonal antibodies,antibody-drug conjugates,cellular therapy,bispecific antibodies,and checkpoint inhibitors.We discuss the genetic and cellular principles of drug resistance that span across all the therapies,as well as some of the unique mechanisms of resistance that are specific to these individual classes of therapies and the strategies that have been developed to address these modes of resistance.展开更多
文摘Peripheral T-cell lymphomas(PTCLs)encompass a biologically diverse group of non-Hodgkin lymphomas derived from mature T-lymphocytes.Most PTCLs present as nodal diseases and include several subtypes characterized by distinct clinical and pathologic features,and will be the focus of this editorial.The PTCL group presenting as rare distinctive extranodal diseases will not be discussed.While T-cell neoplasms,like B-cell lymphomas,recapitulate stages of normal differentiation,the biology is notably intricate and exhibits remarkable plasticity.
文摘Lymphoma is a diverse disease with a variety of different subtypes,each characterized by unique pathophysiology,tumor microenvironment,and underlying signaling pathways leading to oncogenesis.With our increasing understanding of the molecular biology of lymphoma,there have been a number of novel targeted therapies and immunotherapy approaches that have been developed for the treatment of this complex disease.Despite rapid progress in the field,however,many patients still relapse largely due to the development of drug resistance to these therapies.A better understanding of the mechanisms underlying resistance is needed to develop more novel treatment strategies that circumvent these mechanisms and design better treatment algorithms that personalize therapies to patients and sequence these therapies in the most optimal manner.This review focuses on the recent advances in therapies in lymphoma,including targeted therapies,monoclonal antibodies,antibody-drug conjugates,cellular therapy,bispecific antibodies,and checkpoint inhibitors.We discuss the genetic and cellular principles of drug resistance that span across all the therapies,as well as some of the unique mechanisms of resistance that are specific to these individual classes of therapies and the strategies that have been developed to address these modes of resistance.
